Transglutaminase 2 regulates ovarian cancer metastasis by modulating the immune microenvironment

Ovarian cancer is the most lethal gynecological malignancy. Deepening our knowledge of the interactions within the tumor microenvironment (TME) is important for discovering new targeted treatment strategies. Transglutaminase 2 (TG2) is a protein implicated in many biological and pathophysiological p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Frontiers in immunology Jg. 16; S. 1639853
Hauptverfasser:	Ibrahim, Dalia, Grondin, Melanie, Galpin, Kristianne, Asif, Sara, Thompson, Emily, Nersesian, Sarah, Abou-Hamad, John, Echaibi, Maryam, Rodriguez, Galaxia M., Navals, Pauline, Macdonald, Elizabeth, Ryan, Brianna, Cook, David P., Keillor, Jeffrey W., Vanderhyden, Barbara C.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland Frontiers Media S.A 24.07.2025
Schlagworte:	Animals Cell Line, Tumor Disease Models, Animal Female GTP-Binding Proteins Humans immune modulation Immunology metastasis Mice Neoplasm Metastasis ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - immunology Ovarian Neoplasms - pathology Protein Glutamine gamma Glutamyltransferase 2 - antagonists & inhibitors Protein Glutamine gamma Glutamyltransferase 2 - metabolism targeted therapy transglutaminase 2 Transglutaminases - antagonists & inhibitors Transglutaminases - genetics Transglutaminases - metabolism Tumor Microenvironment - immunology Xenograft Model Antitumor Assays targeted therapy transglutaminase 2 immune modulation metastasis ovarian cancer
ISSN:	1664-3224, 1664-3224
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!